Anti-pd-l1 antibody, anti-pd-1 antibody, and the use of inhibitor targeting pd-1/pd-l1 and cox-2 inhibitor

Patent metadata

Field	Value
Publication number	US-2025066483-A1
Application number	US-202418914727-A
Country	US
Kind code	A1
Filing date	Oct 14, 2024
Priority date	Aug 15, 2016
Publication date	Feb 27, 2025
Grant date	—

Abstract

The present disclosure provides an anti-PD-L1 antibody capable of repeated administration even to animals other than rat. The present disclosure further provides a novel therapeutic strategy using an inhibitor targeting PD-1/PD-L1. A pharmaceutical composition which comprises a COX-2 inhibitor and is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1. A potentiator for the immunostimulatory effect of an inhibitor targeting PD-1/PD-L1, which comprises a COX-2 inhibitor. The present disclosure also provides an anti-PD-1 antibody capable of repeated administration even to animals other than rat. An anti-PD-1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLEYSDGYTY (SEQ ID NO: 164), CDR2 having the amino acid sequence of GVS and CDR3 having the amino acid sequence of FQATHDPDT (SEQ ID NO: 165) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFSLTSYY (SEQ ID NO: 166), CDR2 having the amino acid sequence of IRSGGST (SEQ ID NO: 167) and CDR3 having the amino acid sequence of ARTSSGYEGGFDY (SEQ ID NO: 168) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above-described anti-PD-1 antibody as an active ingredient. A method for preparing the anti-PD-1 antibody is also provided.

First claim

1 . A pharmaceutical composition which comprises a COX-2 inhibitor and is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1.

2 . The pharmaceutical composition of claim 1 , wherein the inhibitor targeting PD-1/PD-L1 is an antibody.

3 . The pharmaceutical composition of claim 1 , wherein the antibody is at least one antibody selected from the group consisting of anti-PD-1 antibody and anti-PD-L1 antibody.

4 . The pharmaceutical composition of claim 1 , wherein the COX-2 inhibitor is at least one compound selected from the group consisting of meloxicam, piroxicam, celecoxib, firocoxib, robenacoxib, carprofen and etodolac.

5 . The pharmaceutical composition of claim 1 for use in prevention and/or treatment of cancer and/or infection.

6 . The pharmaceutical composition of claim 1 , wherein the inhibitor targeting PD-1/PD-L1 and the COX-2 inhibitor are administered separately.

7 . The pharmaceutical composition of claim 1 , which is a combination drug comprising the inhibitor targeting PD-1/PD-L1 and the COX-2 inhibitor.

8 . (canceled)

9 . A method of preventing and/or treating cancer and/or infection, comprising administering to a human or animal subject a pharmaceutically effective amount of a COX-2 inhibitor before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1.

10 . An anti-PD-1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLEYSDGYTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of GVS and CDR3 having the amino acid sequence of FQATHDPDT (SEQ ID NO: 165) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFSLTSYY (SEQ ID NO: 166), CDR2 having the amino acid sequence of IRSGGST (SEQ ID NO: 167) and CDR3 having the amino acid sequence of ARTSSGYEGGFDY (SEQ ID NO: 168) and the heavy chain constant region of an antibody of an animal other than rat.

11 . The antibody of claim 10 , wherein the light chain variable region and the heavy chain variable region are derived from rat.

12 . The antibody of claim 11 , wherein the light chain variable region is the light chain variable region of a rat anti-bovine PD-1 antibody and the heavy chain variable region is the heavy chain variable region of a rat anti-bovine PD-1 antibody.

13 . The antibody of claim 12 , wherein the light chain variable region has the amino acid sequence as shown in SEQ ID NO. 149 and the heavy chain variable region has the amino acid sequence as shown in SEQ ID NO: 150.

14 . The antibody of claim 10 , wherein the light chain constant region of an antibody of an animal other than rat has the amino acid sequence of the constant region of lambda chain or kappa chain.

15 . The antibody of claim 10 , wherein the heavy chain constant region of an antibody of an animal other than rat has the amino acid sequence of the constant region of an immunoglobulin equivalent to human IgG4, or has mutations introduced thereinto that reduce ADCC activity and/or CDC activity.

16 . The antibody of claim 15 , wherein the animal other than rat is bovine; the light chain constant region of the bovine antibody has the amino acid sequence of the constant region of lambda chain; and the heavy chain constant region of the bovine antibody has mutations introduced thereinto that reduce ADCC activity and/or CDC activity.

17 . The antibody of claim 16 , wherein the light chain constant region of the bovine antibody has the amino acid sequence as shown in SEQ ID NO: 151 and the heavy chain constant region of the bovine antibody has the amino acid sequence as shown in SEQ ID NO: 152.

18 . The antibody of claim 10 which has a four-chain structure comprising two light chains and two heavy chains.

19 . A pharmaceutical composition comprising the antibody of claim 10 as an active ingredient.

20 . The composition of claim 19 for prevention and/or treatment of cancers and/or inflammations.

21 - 27 . (canceled)

Assignees

• Fuso Pharmaceutical Ind
• Univ Hokkaido Nat Univ Corp

Inventors

• KONNAI Satoru
• Ohashi Kazuhiko
• Murata Shiro
• Okagawa Tomohiro
• Nishimori Asami
• Maekawa Naoya
• Suzuki Yasuhiko
• Nakajima Chie

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61P35/00

  Antineoplastic agents · CPC title